# Prevalence of hearing loss in pseudohypoparathyroidism

**Authors:** Cassandre Djian, Jugurtha Berkenou, Anya Rothenbuhler, Jérémie Botton, Agnès Linglart, Jérôme Nevoux

PMC · DOI: 10.1186/s13023-024-03299-3 · 2024-09-12

## TL;DR

This study finds that nearly 40% of patients with pseudohypoparathyroidism experience hearing loss, with short stature and ectopic ossifications as key predictors.

## Contribution

The study is the first to systematically assess and quantify hearing loss prevalence in PHP/iPPSD patients and identify predictive factors.

## Key findings

- Hearing loss was confirmed in 39% of PHP/iPPSD patients.
- Short stature and ectopic ossifications were significant predictors of hearing loss.
- PHP/iPPSD patients had a 11.4 db average hearing deficit compared to normal controls.

## Abstract

The main clinical features of pseudohypoparathyroidism (PHP)/inactivating parathyroid hormone/parathyroid hormone-related protein signaling disorders (iPPSD), including parathyroid hormone (PTH) resistance, brachydactyly and short stature, develop during middle and late childhood. Very few studies have addressed hearing loss in PHP/iPPSD patients, and these studies have yielded widely divergent conclusions. The aim of our study was to assess hearing and determine the predictive factors of hearing loss in patients with PHP/iPPSD.

Our retrospective cohort study was conducted between March 2019 and May 2020 in the Otolaryngology Department and the calcium phosphate reference center for rare diseases in Bicêtre Paris-Saclay Hospital, France. We retrospectively collected data from patients with PHP/iPPSDs (age, sex, genetic mutations, height, body mass index (BMI), PTH resistance, presence or absence of ectopic ossifications and brachydactyly). All patients underwent auditory investigations, including tonal and vocal audiometry. The primary outcome was the pure tone average (PTA). The PTA was compared with the norm according to the International Organization for Standardization. Hearing loss was defined as a PTA ≥ 20 db.

The median age of the patients was 15.6 years [9.5, 28.5]. Thirty-six patients were diagnosed with iPPSD2, and eight were diagnosed with iPPSD3. Twenty-six of them (59%) were female. Hearing impairment was confirmed in 17 patients (39%). The mean PTA and the mean SRT of the deaf ears were 40 ± 26 db and 31 ± 14 db. The mean difference in the PTA between the patients and the normal controls was 11.4 db (p = 0.00002). Short stature and the presence of ectopic ossifications were two significant predictive factors of hearing loss (p = 0.009 and p = 0.03, respectively). Sex, BMI, PTH resistance, mutation category and brachydactyly were not associated with an increased risk of hearing loss (p = 0.19, p = 0.41, p = 0.13, p = 0.50, p = 0.19, respectively).

Our study confirmed the frequency of hearing loss in patients with PHP/iPPSD disease (prevalence = 39%). A diagnosis of PHP/iPPSD should trigger auditory investigations and follow-up, especially when short stature and/or ectopic ossifications are present.

## Linked entities

- **Diseases:** pseudohypoparathyroidism (MONDO:0019992)

## Full-text entities

- **Genes:** PTH (parathyroid hormone) [NCBI Gene 5741] {aka FIH1, PTH1}, PTHLH (parathyroid hormone like hormone) [NCBI Gene 5744] {aka BDE2, HHM, PLP, PTHR, PTHRP}
- **Diseases:** ectopic ossifications (MESH:D009999), PHP (MESH:D011547), Short stature (MESH:D006130), brachydactyly (MESH:D059327), Hearing impairment (MESH:D034381), iPPSD disease (MESH:D010279)
- **Chemicals:** calcium phosphate (MESH:C020243)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Figures

1 figure with captions in the complete paper: https://tomesphere.com/paper/PMC11396291/full.md

---
Source: https://tomesphere.com/paper/PMC11396291